Key facts
- It has raised $54.0M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Hillhouse Investment Group, CCB International, China-Singapore Suzhou Industrial Park Development Group, Chongqing Boyi Investment, Eisai — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Ractigen Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Ractigen Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ractigen Therapeutics
Developer of medicines designed for the RNA activation field. The company offers treating diseases that arise from inadequate gene expression with several innovative patents, and the key therapeutic areas include central nervous system diseases, tumors, liver diseases, and ophthalmic diseases, thereby providing customers with innovative and efficient products.
- Sector
- Healthcare
- HQ
- Nantong, China
- Founded
- 2016
- Employees
- 50
- Website
- cn.ractigen.com/
- Ownership
- Privately Held (backing)
Ractigen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ractigen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ractigen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.